Evidence map›Paper›PMID 41769184›Full record

ArticleRadiology case reports2026

A multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging.

Omar Ibrahim, Nicholas S Cho, Viên Lam Le, Francesco Sanvito, Jingwen Yao, Ashley Teraishi, Albert Lai, Phioanh L Nghiemphu, Noriko Salamon, Fausto J Rodriguez and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Omar IbrahimUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.
Nicholas S ChoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.
Viên Lam LeUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.
Francesco SanvitoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.
Jingwen YaoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.
Ashley TeraishiUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.
Albert LaiUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Phioanh L NghiemphuUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Noriko SalamonDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Fausto J RodriguezDepartment of Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Richard EversonDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Timothy F CloughesyUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA, USA.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

We present a rare case of concurrent, spatially distinct 1p/19q-intact IDH-mutant astrocytoma and 1p/19q-codeleted IDH-mutant oligodendroglioma in the same patient with divergent responses to IDH inhibitor therapy. A 40-year-old male presented to the emergency room following a seizure and was found to have 2 distinct left hemisphere tumors. Both lesions underwent biopsy and resection, with updated molecular diagnosis 4 years later revealing IDH-mutant 1p/19q-intact astrocytoma and IDH-mutant 1p/19q-codeleted oligodendroglioma. Tumor volumes, T2-FLAIR mismatch percentage, and normalized apparent diffusion coefficient (nADC) were quantified from serial MRIs. At initial presentation, quantitative analysis revealed the posterior lesion (IDH-mutant 1p/19q-intact astrocytoma) exhibited 60.6% T2-FLAIR mismatch volume and elevated median nADC of 2.72, while the anterior lesion (IDH-mutant 1p/19q-codeleted oligodendroglioma) showed minimal T2-FLAIR mismatch (1.8%) and lower median nADC (1.94). Volumetric analysis during IDH inhibitor (ivosidenib) therapy revealed differential response: the oligodendroglioma decreased in volume by 32.6% over 19 months, while the astrocytoma demonstrated progressive growth with a 77.3% volume increase over 19 months. This case demonstrates the utility of quantitative neuroimaging for accurate characterization of concurrent IDH-mutant gliomas with distinct molecular profiles. The observed differential response to IDH inhibition supports emerging evidence of molecular subtype-specific treatment sensitivities in IDH-mutant gliomas.

Indexed as

IDH-mutant astrocytomaIDH-mutant oligodendrogliomaIvosidenibMRIT2-FLAIR mismatch

Identifiers

PMID41769184
PMCPMC12936475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.